Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.

Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, Merkel PA, Calamia KT, Liu Z, Pineda L, Stevens RM, Yazici H, Yazici Y.

N Engl J Med. 2015 Apr 16;372(16):1510-8. doi: 10.1056/NEJMoa1408684.

PMID:
25875256
2.

[Weight gain during treatment with thalidomide: a case report].

Comte H, Béné J, Auffret M, Gautier S, Salle-Staumont D.

Therapie. 2014 Sep-Oct;69(5):457-9. doi: 10.2515/therapie/2014055. Epub 2014 Oct 7. French.

PMID:
25285366
3.

Severe primary ocular surface involvement in Behcet disease.

Zeng J, Chen B.

Optom Vis Sci. 2014 Dec;91(12):e301-4. doi: 10.1097/OPX.0000000000000405.

PMID:
25279778
4.

Mucocutaneous ulceration in a previously healthy man.

Aslam A, Chalmers R.

J Fam Pract. 2014 Feb;63(2):97-100. No abstract available.

PMID:
24527472
5.

Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report.

Li Y, Han Z, Wang X, Mo Z, Zhang W, Li A, Liu S.

BMC Gastroenterol. 2013 Dec 9;13:167. doi: 10.1186/1471-230X-13-167.

6.

[An analysis of adverse drug reactions of thalidomide in treatment of immune-related bowel diseases].

Luo HQ, Tan B, Lü H, Qian JM.

Zhonghua Nei Ke Za Zhi. 2013 Sep;52(9):726-9. Chinese.

PMID:
24314159
7.

The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.

Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, Hirai F, Nagahori M, Matsushita M, Kobayashi K, Kishimoto M, Takeno M, Tanaka M, Inoue N, Hibi T.

J Gastroenterol. 2014 Jan;49(1):156-62. doi: 10.1007/s00535-013-0872-4. Epub 2013 Aug 18.

8.

[Current therapeutic indications of thalidomide and lenalidomide].

Ordi-Ros J, Cosiglio FJ.

Med Clin (Barc). 2014 Apr 22;142(8):360-4. doi: 10.1016/j.medcli.2013.04.038. Epub 2013 Jul 3. Review. Spanish.

PMID:
23830554
9.

Recurrent aortic aneurysm due to Behcet's disease: a case report from China.

Zhang Z, Jian X, Liu H, Zhang W, Zhou Q.

Ann Thorac Cardiovasc Surg. 2013;19(2):173-5. Epub 2012 Aug 20.

10.

Frequent oral ulceration during early disease may predict a severe disease course in males with Behçet's syndrome.

Hamuryudan V, Hatemi G, Sut N, Ugurlu S, Yurdakul S, Yazici H.

Clin Exp Rheumatol. 2012 May-Jun;30(3 Suppl 72):S32-4. Epub 2012 Oct 8.

PMID:
22935508
11.

Adamantiades-Behcet's disease-complicated gastroenteropathy.

Wu QJ, Zhang FC, Zhang X.

World J Gastroenterol. 2012 Feb 21;18(7):609-15. doi: 10.3748/wjg.v18.i7.609. Review.

12.

Behçet disease: clinical features and management in a Brazilian tertiary hospital.

Oliveira AC, Buosi AL, Dutra LA, de Souza AW.

J Clin Rheumatol. 2011 Dec;17(8):416-20. doi: 10.1097/RHU.0b013e31823a46ed.

PMID:
22089985
13.

[Pyoderma gangrenosum and Behçet's disease: a study of two pediatric cases].

Hali F, Khadir K, Chiheb S, Bouayad K, Mikou N, Benchikhi H.

Arch Pediatr. 2011 Dec;18(12):1320-3. doi: 10.1016/j.arcped.2011.09.007. Epub 2011 Oct 24. French.

PMID:
22030347
14.

Clinical response to thalidomide and colchicine in two siblings with Behcet's disease carrying a single mutated MEFV allele.

Rigante D, La Torre F, Calcagno G, Falcini F.

Rheumatol Int. 2012 Jun;32(6):1859-60. doi: 10.1007/s00296-011-2046-0. Epub 2011 Jul 22. No abstract available.

PMID:
21833519
15.

Synthesized pyridine compound derivatives decreased TNF alpha and adhesion molecules and ameliorated HSV-induced inflammation in a mouse model.

Choi B, Kim J, Lee ES, Bang D, Sohn S.

Eur J Pharmacol. 2011 Apr 25;657(1-3):167-72. doi: 10.1016/j.ejphar.2011.01.062. Epub 2011 Feb 17.

PMID:
21315710
16.

[Thalidomide as immunomodulatory drug: pharmacological actions and its indications].

Yasui K.

Nihon Rinsho Meneki Gakkai Kaishi. 2010;33(5):229-33. Review. Japanese.

17.

Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.

Ladizinski B, Shannon EJ, Sanchez MR, Levis WR.

J Drugs Dermatol. 2010 Jul;9(7):814-26. Review.

PMID:
20677538
18.

[Recurrent aphthosis: safety of low dose thalidomide].

Gil H, Perrin S, Dupond JL, Meaux-Ruault N, Hafsaoui C, Limat S, Magy-Bertrand N.

Rev Med Interne. 2010 Jun;31(6):403-5. doi: 10.1016/j.revmed.2009.12.008. French.

PMID:
20430488
19.

Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial.

Hamuryudan V, Hatemi G, Tascilar K, Sut N, Ozyazgan Y, Seyahi E, Mat C, Yurdakul S, Yazici H.

Rheumatology (Oxford). 2010 Jan;49(1):173-7. doi: 10.1093/rheumatology/kep350.

20.

The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis.

Siva A, Saip S.

J Neurol. 2009 Apr;256(4):513-29. doi: 10.1007/s00415-009-0145-6. Epub 2009 Apr 27. Review.

PMID:
19444529
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk